NVS novartis.com: Indikator likuiditas cepet

Novartis AG operates advanced production facilities for radioligand therapies. Revenues are based on the sale of patented drugs for oncology and cardiac pathologies. A strategic focus on gene therapy provides a technological edge. This quick liquidity chart demonstrates the ability to cover debts excluding inventories, with the value stabilizing at 0.72, confirming the holding's financial stability.

Novartis AG (NVS) actively delegates molecule development and production to external contractors, which optimizes working capital. This model makes calculations sensitive to cash volume and accounts receivable, excluding slow-moving inventories. The metric determines immediate solvency by assessing the ability to settle short-term obligations without relying on warehouse stocks. The trend of the acid-test ratio demonstrates the balance between financial security and capital efficiency.